ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A

Also written as “MHB039A for Injection” and “MHB039A”.

Its studies are mostly in Breast Neoplasms, led by Minghui Pharmaceutical.

Drug pageAnti-PD-1/Anti-VEGF Bispecific Antibody MHB039A: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 18, 20243 company-led studies, 3 open or runningNext primary completion: Apr 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Minghui Pharmaceutical33 open or runningphase 2since Mar 18, 2024Mar 18, 2024Apr 1, 2028phase 2 · NCT06345482

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 18, 2024First study: phase 2 study in Advanced Solid TumorFirst studyNCT06345482 · 196 enrolled · China
  2. Aug 11, 20252 phase 2 studiesNCT07126665, NCT07130383

Ahead

  1. Apr 1, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT06345482
  2. Aug 2029Primary completion: phase 2 study in Advanced Breast CancerNCT07130383
  3. Aug 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07126665

TargetBeta

PDCD1 →VEGFA →read by rule
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07130383Advanced Breast Cancer · China2RecruitingAug 2029210
NCT07126665Advanced Malignant Solid Tumor · China2RecruitingAug 2029116
NCT06345482Advanced Solid Tumor · China2Active, not recruitingApr 1, 2028196

How it is read

Names in the registry

  • “MHB039A for Injection”, 2 entries
  • “MHB039A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.